Bye Bye CFDA, Hello NMPA: China Regulatory Express
Executive Summary
In the latest in a series of regulatory changes in China, the national drugs regulator has apparently been renamed the National Medical Products Administration (NMPA), while the country's essential drugs list has been expanded to include more oncology and pediatric drugs, which will be fully reimbursed.
You may also be interested in...
China Vs. Cancer: Seven Companies Given Price Cuts, Roche Gets New Approval
Cancer drug prices again on the chopping board in China, including for some products already affected, and more are coming.
China Regulatory Shakeup: Top Regulator Out, Commissioner Reprimanded Amid Vaccine Scandal
Amid aftermath of latest vaccine scandal, top officials including China’s drug reform flagbearer are forced to resign, sending shock waves across the industry.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues.